Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

TREM2MEDS Towards the clinical implementation of TREM2 Microglia Engineering for treating DementiaS

Coordinator
Universita Degli Studi Di Padova, Italy
Runs
1 April 2024 to 31 March 2027
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
4 organisations in 3 countries
Type
European Innovation Council
Grant agreement
101159096

What the project is doing

In the project's own words, from its summary on CORDIS.

TREM2MEDS emerges from the ERC PoC 2022 project TREM2μENGINES (Grant agreement ID: 101069395), which validated the efficacy of a novel treatment for Alzheimer’s Disease (AD) and Nasu-Hakola Disease (NHD) in murine models. A relevant proportion of AD cases and all forms of NHD are caused by pathogenic mutations in the TREM2 gene, which lead to microglia dysfunction contributing to and/or causing the onset and manifestations of AD and NHD.

TREM2MEDS approach involves the transplantation of hematopoietic stem/progenitor cells (HSPCs) engineered by lentiviral vectors (LVs) to express robust levels of the Triggering receptor expressed on myeloid cells 2 (TREM2) in their central nervous system (CNS) myeloid/microglial progeny. The engineered cells have shown the ability to reduce and prevent Aβ accumulation, mitigate neuroinflammation and restore physiological scavenging functions in the diseased CNS, benefiting AD and NHD in robust animal models.

In TREM2MEDS, we will exploit these findings for transition of the approach from TRL 4 to TRL 5/6 by generating IMPD-enabling data and packages that will allow launching, at project completion, a first-in-human Phase I clinical trial of TREM2-HSPC gene therapy in AD & NHD patients carrying TREM2 hypofunctional variants. The restoration of TREM2 function in microglia, by intervening on key mechanisms contributing to neurodegeneration, has the potential to overcome the limited efficacy of current treatments for AD, which only exert symptomatic but not curative effects.

Through this work we will thus bring to clinical testing an approach intended to become the benchmark in the treatment of AD and NHD, and possibly other dementias.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di PadovaPadovaItalyCoordinator
Ustav Molekularni Genetiky Av Cr V.v.i.Praha 4CzechiaParticipant
Institut National De La Sante Et De La Recherche MedicaleParisFranceParticipant
Unismart - Fondazione Universita Degli Studi Di PadovaPadovaItalyThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI